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4  
3 Individualised pelvic floor muscle training in women 
4 with pelvic organ prolapse: a multicentre 
5 randomised controlled trial 
6 
 
7 Abstract 
 
8 Background Pelvic organ prolapse is common and is strongly associated with childbirth and increasing age. 
9 Women with prolapse are often advised to do pelvic floor muscle exercises, but supporting evidence is limited. 
10 Our aim was to establish if one-to-one individualised pelvic floor muscle training (PFMT) is effective in reducing 
11 prolapse symptoms. 
12 
13 Methods A parallel-group multicentre randomised controlled trial (ISRCTN35911035) in female outpatients with 
14 newly-diagnosed, symptomatic stage I, II or III prolapse, comparing five PFMT appointments over 16 weeks 
15 (n=225) versus a lifestyle advice leaflet (n=222). Treatment allocation was by remote computer allocation using 
16 minimisation. Our primary endpoint was participants’ self-report of prolapse symptoms at 12 months. Group 
17 assignment was masked from outcome assessors. We compared outcomes between trial groups in an intention- 
18 to-treat analysis. The cost of PFMT and savings on subsequent treatments were calculated to estimate cost- 
19 effectiveness. 
20 
21 Findings Compared to the control group, the intervention group reported fewer prolapse symptoms at 12 months 
22 (mean difference between groups in change score 1.52, 95% CI [0.46, 2.59], p=0.0053); reported their prolapse 
23 to be “better” more often (57.2% versus 44.7%, difference 12.6%, 95% CI [1.1%, 24.1%], p=0.0336); and had an 
24 increased but non-significant odds of having less severe stage of prolapse at their 6-month clinical examination, 
25 (OR 1.47, 95% CI [0.97, 2.27], p=0.07). The control group had a greater uptake of other prolapse treatment 
 
26 (49.6% versus 24.1%, difference 25.5%, 95% CI [14.5%, 36.0%], p<0.0001). Findings were robust to missing 
 
27 data. The net cost of the intervention was £131.61 per woman and the cost per one-point reduction in the 
28 symptom score was £86.59, 95% CI [£50.81, £286.11]. 
29 
30 Interpretation One-to-one PFMT for prolapse is effective in improving prolapse symptoms. Longer-term benefits 
31 should be investigated, as should the effects in specific subgroups. 
32 
33 Funding Chief Scientist Office, Scottish Government Health Directorates; New Zealand Lottery Board; National 
34 Health and Medical Research Council Australia (Grant number 508925). 
35 Word count 308 
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5  
3 Introduction 
 
4 Pelvic organ prolapse is a common female condition, with 40% of women over the age of 50 years having 
 
5 some degree of prolapse on examination.1  Approximately 11% of all women undergo surgery for urinary 
 
6 incontinence or prolapse during their lifetime, and 7% for prolapse alone.2 In England around 29,000 prolapse 
 
7 repairs were performed in 2010/20113 at a cost of around £60m, and surgery numbers are likely to increase 
 
8 substantially as the population ages.4  Increasing age and parity, and family history of prolapse have been 
 
9 reported as the main risk factors for prolapse, although factors such as obesity, heavy lifting and constipation 
 
10 may also play a role.5 One study reported a total population-attributable risk for prolapse of 46% associated 
 
11 with having prolapse symptoms during pregnancy, a mother with prolapse, and undertaking heavy physical 
 
12 work.6 Prolapse is characterised by symptomatic descent of the vaginal walls, apex or vault from the normal 
 
13 anatomical position.7  Women with prolapse may present with vaginal, bladder, bowel, back, abdominal and 
 
14 sexual symptoms. The condition can affect daily activities and quality of life. Current treatment options include 
 
15 surgery and conservative management, the latter being considered if the prolapse is less severe or the woman 
 
16 is a poor candidate for surgery. Conservative interventions include: physical interventions which aim to improve 
 
17 pelvic floor muscle function and support via pelvic floor muscle training (PFMT); mechanical interventions 
 
18 which aim to support the prolapse (e.g. use of vaginal pessaries); and lifestyle interventions which seek to 
 
19 avoid exacerbation of the prolapse by decreasing intra-abdominal pressure (e.g. weight loss, avoiding heavy 
 
20 lifting). 
 
21 
 
22 Many physiotherapists who specialise in women’s health offer women with prolapse individualised PFMT.8 The 
 
23 aim of PFMT is to improve pelvic floor muscle function (strength, endurance and coordination) and ultimately 
 
24 increase the structural support for the pelvic organs. There is evidence that PFMT is effective in the treatment 
 
25 of urinary incontinence9  but the evidence for PFMT in the management of prolapse is less clear. The 
 
26 Cochrane systematic review updated in 201110 identified four trials (including two pilot trials) comparing PFMT 
 
27 with control, two of which were at significant risk of bias. Symptoms, although measured differently in different 
 
28 studies, were improved in the short-term in three trials, and pooled data on severity from two trials indicated 
 
29 an improvement post-treatment in prolapse stage due to PFMT. The review concluded that reliable evidence 
6  
3 relating to effectiveness and cost-effectiveness of PFMT for symptomatic prolapse in the medium and long 
 
4 term is needed. 
 
5 
 
6 We  report  findings  of  the  Pelvic  Organ  Prolapse  PhysiotherapY  (POPPY)  trial  which  compared  an 
 
7 individualised PFMT programme compatible with UK NHS practice (five one-to-one appointments over 16 
 
8 weeks), with a control group allocated to a prolapse lifestyle advice leaflet and no PFMT. Our hypothesis was 
 
9 that, in women with stage I to III prolapse of any type, one-to-one pelvic floor muscle training, as compared to 
 
10 a lifestyle advice leaflet, would reduce the symptoms of prolapse and the need for further prolapse treatment, 
 
11 and that it would be a cost-effective treatment for prolapse. 
 
12 
13 Methods 
 
14 Participants 
 
15 Between September 2007 and February 2010 we identified new attendees at outpatient gynaecology clinics 
 
16 presenting with symptomatic prolapse in 25 centres (23 UK; 1 Dunedin, New Zealand; 1 Sydney, Australia). 
 
17 Centres were a mix of university teaching hospitals and district general hospitals, all offering similar specialist 
 
18 pelvic floor physiotherapy services. Women were asked to take part if stage I, II or III prolapse of any type 
 
19 (anterior, posterior, apical, or a combination) was confirmed by their gynaecologist on vaginal examination 
 
20 using the Pelvic Organ Prolapse Quantification (POP-Q) measurement system,11  and if prolapse was their 
 
21 main presenting complaint. 
 
22 
 
23 We excluded women if they had had previous prolapse treatment including surgery, if they were pregnant or 
 
24 less than six months post-natal, or if they were unable to comply with the intervention (i.e. if they were not 
 
25 able to attend the clinic for appointments with the physiotherapist). Women who, on examination, were 
 
26 deemed to need treatment for vaginal atrophy were eligible after completing a course of local oestrogens. 
 
27 
 
28 The trial methods were based on our pilot trial findings.12  Women gave signed informed consent to being 
 
29 randomised and to long-term follow-up. Our trial was carried out in accordance with the Declaration of 
 
30 Helsinki. It was approved by: Scotland A Research Ethics Committee, Edinburgh, Scotland; Lower South 
7  
3 Regional Ethics Committee, Ministry of Health, Dunedin; Human Research Ethics Committees of The University 
 
4 of Melbourne, Victoria, Australia and St George Hospital, Kogarah, New South Wales, Australia. It was 
 
5 overseen by an independent Trial Steering Committee (TSC) and a separate, independent Data Monitoring 
 
6 Committee (DMC). 
 
7 
8 Procedures 
 
9 Women allocated to the intervention were invited to attend five one-to-one PFMT appointments over 16 weeks 
 
10 (at weeks 0, 2, 6, 11 and 16) with a women’s health physiotherapist. The intervention duration of 16 weeks 
 
11 was chosen on the basis of both muscle physiology (15 weeks specific muscle training is required to gain 
 
12 muscle hypertrophy13) and UK clinical guidelines for the management of urinary incontinence recommend 
 
13 PFMT for “at least 3 months”.14 Appointment frequency was based on current practice within the UK NHS; first 
 
14 appointments close together to allow reinforcement of correct exercise technique and understanding of all 
 
15 advice given, later appointments becoming further apart to encourage independent home exercise. 
 
16 
 
17 At the first appointment an explanation of types of prolapse, pelvic floor muscle anatomy and function were 
 
18 given using diagrams and a model pelvis. Internal pelvic floor muscle assessment to correct exercise technique 
 
19 and assess muscles (using the PERFECT Scheme)15  was completed. An individualised home exercise 
 
20 programme was prescribed based on examination findings. Women were encouraged to progress exercises, 
 
21 aiming for ten times ten second maximal holds and up to fifty fast contractions, three times per day and to 
 
22 record all exercises in a diary. Women were also taught how to pre-contract the pelvic floor muscles against 
 
23 increases in intra-abdominal pressure (“the knack”) and encouraged to use this technique daily. The home 
 
24 exercise programme was modified at each appointment as indicated by examination findings and diary 
 
25 recordings. The use of electromyography biofeedback, pressure biofeedback and electrical stimulation were not 
 
26 permitted. Trial physiotherapists attended training prior to their involvement in intervention delivery within the 
 
27 trial. No additional training was given to physiotherapists during intervention delivery. 
 
28 
8  
3 Participants received a lifestyle advice leaflet that gave advice about weight loss, constipation, avoidance of 
 
4 heavy lifting, coughing and high impact exercise: control women received this by post, whilst intervention group 
 
5 women received it at their first appointment. The leaflet contained no information about pelvic floor muscle 
 
6 exercises or techniques. Women attended a review appointment with their gynaecologist at six months post- 
 
7 trial entry, at which time they could be referred for further prolapse treatment if desired. 
 
8 
9 We used postal questionnaires to collect data at the time of trial entry (baseline), and at 6 and 12 months 
 
10 after trial entry. Our primary clinical endpoint was prolapse symptoms at 12 months as measured by the Pelvic 
 
11 Organ Prolapse Symptom Score (POP-SS),16  a validated, patient-completed instrument with seven items, 
 
12 relating to frequency of prolapse symptoms over the previous four weeks, each scored from 0 (never) to 4 (all 
 
13 of the time) (total score 0 to 28). Secondary outcomes included: women’s perceived change in prolapse since 
 
14 the start of the study (same, better, worse); quality of life measured as interference of prolapse symptoms with 
 
15 everyday life (scored 0 ‘not at all’ to 10 ‘a great deal’); number of days with prolapse symptoms in the 
 
16 previous four weeks; uptake of further prolapse treatment (surgery, ring pessary, referral to physiotherapy, 
 
17 referral to dietician, oestrogen cream/tablets or HRT); impact of incontinence (International Consultation on 
 
18 Incontinence Questionnaire Urinary Incontinence Short Form - ICIQ UI SF – scored 0 to 21, higher values 
 
19 indicating greater severity)17; bowel symptoms (early short form version of ICIQ bowel symptom questionnaire 
 
20 provided  by  the  developers);  sexual  symptoms  (Pelvic  Organ  Prolapse/Urinary  Incontinence  Sexual 
 
21 Questionnaire, PISQ-12)18; general health (SF-12)19; use of health services in primary and secondary care; 
 
22 and frequency of the practice of pelvic floor muscle exercises in last 4 weeks (a few times only, once a week, 
 
23 a few times a week, once a day, a few times a day, and contractions per day: <5, 5–10, 11–20, 21–30, 31– 
 
24 60, >60). Intervention adherence was measured in terms of attendance at appointments and the amount of 
 
25 exercise women recorded in their daily exercise diary. In addition, the physiotherapists delivering the 
 
26 intervention collected data at each appointment about women’s adherence to the prescribed exercise. 
 
27 
 
28 Assessment of prolapse type and stage by the gynaecologist in clinic was carried out in all women before 
 
29 group allocation and at the 6-month review appointment using the POP-Q system.11  Formal POP-Q training 
9  
3 was given at each trial centre initiation visit. This included: a verbal explanation of POP-Q system; observation 
 
4 of the American Urogynecological Society POP-Q training DVD; information on standardising conditions for 
 
5 POP-Q examination (e.g. examination position, bladder emptying, equipment use); use of the recording form 
 
6 and a question and answer session. Each centre was provided with a copy of the DVD and the publication 
 
7 describing the POP-Q.11 Centres were encouraged to carry out further in-house training, and additional centre 
 
8 visits were offered if necessary. 
 
9 
 
10 
 
11 Group allocation and masking 
 
12 Women were allocated to groups using the remote-computer determined randomisation application at the 
 
13 Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, UK. 
 
14 Treatment allocation used minimisation to balance group sizes on key prognostic factors at baseline. These 
 
15 were centre, stage of prolapse (I, II or III), and the woman’s motivation for prolapse surgery (not considering 
 
16 surgery/considering surgery). The latter is potentially an important factor influencing how adherent women will 
 
17 be to PFMT. The university-based trial coordinator accessed the web-based application and then informed the 
 
18 woman, and the physiotherapist as necessary, of the allocated group. The intervention could not be masked 
 
19 from women or treating physiotherapists. Outcome assessment was by participant-completed questionnaires, 
 
20 thus avoiding assessor bias: data entry was carried out blinded to group allocation. The gynaecologist 
 
21 undertaking the POP-Q assessment at 6 months was blinded to women’s trial group until after the 
 
22 examination. 
 
23 
 
24 Sample size 
 
25 We estimated a difference between groups in mean POP-SS of 2.5 as our effect size, based on the pilot 
 
26 trial.12 With 253 women per group the trial had 80% power at the 5% significance level to detect a different of 
 
27 2.5 points in the primary outcome measure, assuming a common standard deviation (SD) of 8 points.20 This 
 
28 calculation allowed for 10% loss to follow-up overall, and 15% of the control group receiving all of the benefit 
 
29 of PFMT by undertaking exercises under their own initiative. 
1
0 
 
3 
 
4 Statistical analysis 
 
5 We tabulated descriptive statistics, reporting baseline demographics and clinical characteristics with means and 
 
6 SDs, or median and inter-quartile range (IQR) as appropriate. We used intention-to-treat analyses to compare 
 
7 the primary outcome at 12 months by fitting a linear mixed effects model to change from baseline in POP-SS 
 
8 at 6 and 12 months, with a random intercept for subject within centre and a random slope for time within 
 
9 subject, and adjusted for baseline POP-SS score and the minimisation variables. Such models implicitly adjust 
 
10 the model estimates where there are missing data, assumed them to be missing at random, according to 
 
11 observed values.21  Women who had observations at baseline and at least one follow-up time-point were 
 
12 included in the model. The difference between the intervention and control groups in estimated mean change 
 
13 from baseline was presented for 6 and 12 months with 95% confidence intervals and p-values. We also 
 
14 assessed the assumption of missing at random and corresponding impact of missing responses on the primary 
 
15 outcome using multiple imputation.22 Model assumptions were checked using residual plots and found to hold. 
 
16 
 
17 POP-Q stage was compared between groups in an ordinal regression model with 6 month POP-Q stage as 
 
18 the dependent variable, and baseline POP-Q stage and minimisation variables as covariates. The pooled odds 
 
19 ratio from the ordinal model was calculated with a 95% confidence interval and p-value. Stage II prolapse was 
 
20 subdivided depending on whether the prolapse was above the hymen, or at the hymen or below. Change in 
 
21 POP-Q stage between baseline and six months was also presented. Other secondary outcomes were 
 
22 compared between groups using the Mann-Whitney (M-W) test for continuous and ordinal variables and the 
 
23 chi-squared or Fisher’s exact test for categorical variables. 
 
24 
 
25 Through planned subgroup analyses we explored the effect on the primary outcome of prolapse stage and 
 
26 type, age and motivation for surgery, using stricter levels of statistical significance (two-sided p<0·01). 
 
27 
10  
3 Analyses were conducted according to a pre-specified Statistical Analysis Plan using the R programming 
 
4 package23 and the mi package in R24 for post-hoc multiple imputation analysis. The analyst was independent 
 
5 of the research team and was blinded to group allocation until after the main analysis had been undertaken. 
 
6 
 
7 Economic analysis 
 
8 Our economic assessment was a within-trial analysis at 12 months after recruitment taking an NHS cost 
 
9 perspective. Direct health-service costs were used to generate the total cost for each participant. Based on the 
 
10 number of trial physiotherapy appointments attended, we estimated the amount of physiotherapy time which 
 
11 was involved in the delivery of the intervention and the associated costs of clinic space. All women were 
 
12 asked in follow-up questionnaires about their use of health services (general practitioner, practice nurse 
 
13 consultations) and any further prolapse treatment they had received. Costs were attributed to these items 
 
14 using UK data from: Personal Social Services Research Unit, Unit Costs of Health and Social Care; Scottish 
 
15 Health Service Costs; British National Formulary; and C&G Medicare Limited.25–28  The costs were balanced 
 
16 against changes in the primary clinical outcome. We assumed that where we observed a difference between 
 
17 the trial groups in rates of subsequent treatments such as surgery at the end of the trial follow-up period, 
 
18 these represented savings. Sensitivity analyses were performed to assess the possible impacts of varying the 
 
19 intervention effect size and the uptake of subsequent prolapse treatment. 
 
20 
 
21 This trial is registered with Current Controlled Trials, number ISRCTN35911035. 
 
22 
 
23 Role of the funding source 
 
24 The funders of the study had no role in trial design, data collection, data analysis, data interpretation, or 
 
25 writing of the report. GM, JN, SB, AE, SH and AW had access to trial data. All authors agreed to submit for 
 
26 publication. 
 
27 
 
28 Results 
 
29 We approached 2093 women attending outpatient gynaecology clinics of whom 603 were eligible and 447 
 
30 (74%) consented to take part in the trial (Figure 1). Follow-up rates for questionnaires were 85% (381/447) 
11  
3 at 6 months and 66% (295/447) at 12 months; 77% (365/477) attended for 6-month review. Non- 
 
4 responders at 12 months were significantly younger and had a higher BMI than responders. There was no 
 
5 evidence of differential dropout between the trial groups. The mean age of participants was 56.8 years (SD 
 
6 11.5); the median number of births per woman was 2 (range 0 to 7); 412/445 (92.6%) of women had had 
 
7 at least one vaginal birth, 28/447 (6.3%) had had at least one caesarean section, 118/445 (26.5%) had 
 
8 had at least one forceps delivery, and 9/447 (2.0%) had had a vacuum extraction. Women were on average 
 
9 in the overweight category (mean BMI 27, SD 5.1). The most common presentation was combined anterior, 
 
10 posterior and upper compartment prolapse (202/445 (45.4%)), followed by combined anterior and posterior 
 
11 (108/445 (24.3%)). Most women (338/447 (75.6%)) had stage II prolapse (95/447 (21.3%) above the 
 
12 hymen, 243/447 (54.4%) at or below the hymen). Median duration of prolapse symptoms was 12 months 
 
13 (IQR 6 to 24). As expected for a trial of this size, the trial groups were well-balanced on clinical and 
 
14 demographic factors at baseline (Table 1). 
 
15 
 
16 Intervention adherence 
 
17 Of the women allocated to the intervention group, 80% (178/222) attended 4 or 5 out of the possible 5 
 
18 physiotherapy appointments over the 16 week intervention period (Table 2). Adherence to the prescribed 
 
19 number of sets of exercise or greater between appointments was achieved by just under three quarters of 
 
20 women. Women in the intervention group were more likely than those in the control group, although not 
 
21 significantly so, to report performance of pelvic floor exercises in the last four weeks at 12-month follow-up 
 
22 (115/147 (78%) versus 95/138 (69%); risk difference 9.4%, 95% CI [-0.8%, 19.6%], p=0.07; risk ratio 
 
23 1.13, 95% CI [0.96, 1.34], p=0.15). 
 
24 
 
25 Adverse effects 
 
26 Eight adverse events (6 vaginal symptoms, 1 back pain, 1 abdominal pain) and one unexpected serious 
 
27 adverse event (skiing injury), defined as affecting normal everyday activities, were reported by participants; all 
 
28 were from women in the intervention group. None of these were judged to be related to the intervention or to 
 
29 trial participation. 
12  
3 
 
4 Prolapse outcomes 
 
5 Women in the intervention group reported more improvement in prolapse symptoms (a significantly greater 
 
6 reduction in POP-SS) compared to the control group both at 6 months (difference between groups in change 
 
7 from baseline 2.84, 95% CI [2.05, 3.63], p<0.0001) and at 12 months (1.52, 95% CI [0.46, 2.59], 
 
8 p=0.0053) (Table 3). Combining the results of refitting the model to five imputations of the missing POP-SS 
 
9 scores gave very similar estimates of the differences between the groups (6 months: 2.79, 95% CI [1.91, 
 
10 3.67], 12 months: 1.66, 95% CI [0.74, 2.58]). 
 
11 
 
12 The most commonly reported symptom at baseline was “a feeling of something coming down” (around 90% in 
 
13 both groups, Table 1); this persisted at 6 and 12 months (Table 3). All POP-SS symptoms were significantly 
 
14 less common in the intervention group at 6 months, and for “discomfort worse when standing” and “lower 
 
15 abdominal heaviness” this was true at 12 months also (Table 3). Women in the intervention group were also 
 
16 less likely to report having prolapse symptoms in the last 4 weeks both at 6 and 12 months (Table 3). 
 
17 
 
18 When asked “how do you feel your prolapse is now compared to the start of the study?”, intervention women 
 
19 were significantly more likely than controls to report their prolapse was “better”, both at 6 months (98/187 
 
20 (52%) versus 32/189 (17%), M-W p<0.0001) and 12 months (83/145 (57%) versus 63/141 (45%), M-W 
 
21 p=0.0125) (Table 3). 
 
22 
 
23 After adjusting for baseline POP-Q stage, centre and whether the woman was motivated to have surgery, the 
 
24 odds of a less severe prolapse stage at six months was greater in the intervention group although this was not 
 
25 significant (OR 1.47, 95% CI [0.97, 2.27], p=0.07). A greater proportion of women in the intervention group 
 
26 had an improvement in their prolapse stage by 6 months (45/168 (26.8%) versus 33/171 (19.3%), Table 5) 
 
27 but this was not significant (risk difference 7.5%, 95% CI [-1.4%, 16.4%], p=0.10; risk ratio 1.39 [95% CI 
 
28 0.94 to 2.06], p=0.10). 
 
29 
13  
3 Effect of prolapse on quality of life and other clinical outcomes 
 
4 Women were asked to report how much prolapse interfered with dimensions of their quality of life and about 
 
5 other symptoms (Table 4). At 6 months the intervention group scores were significantly lower (better) in all 
 
6 aspects of daily life, and sexual, bladder and bowel function (except for faecal incontinence), but this was not 
 
7 evident at 12 months (Table 4). 
 
8 
 
9 
 
10 Further prolapse treatment 
 
11 We asked women what further prolapse treatment they had received. By 12 months, significantly more control 
 
12 women (71/143 (49.6%)) reported they had received further treatment compared to the intervention women 
 
13 (35/145 (24.1%)) (risk difference 25.5%, 95% CI [14.5%, 36.0%], p<0.0001; risk ratio 2.1, 95% CI [1.5, 
 
14 2.9], p<0.0001). There was a similar uptake of surgery, pessary and other non-trial treatments in the trial 
 
15 groups by 12 months, but significantly more control women had received a physiotherapy referral for PFMT 
 
16 (Table 5). 
 
17 
 
18 Subgroups 
 
19 The treatment effect at 12 months was consistent for all subgroups pre-specified in the analysis plan. That is, 
 
20 there were no significant interactions between trial group and any of the subgroup terms in the model: 
 
21 prolapse stage (I to III) (p=0.38), prolapse type (most descended part anterior/posterior/upper) (p=0.61), 
 
22 age (under 50/50 years or over) (p=0.29); and motivation for surgery (keen/wants to avoid) (p=0.89). 
 
23 
 
24 Costs and benefits 
 
25 The cost of the physiotherapy intervention was £170.24 based on an hourly cost of a Band 6 physiotherapist 
 
26 of £30.67.25 Trial physiotherapists reported initial appointments took 80 minutes (60 minutes face-to-face plus 
 
27 20 minutes of administration); follow-up appointments (maximum of 4) took 40 minutes. For overheads such 
 
28 as the cost of the examination room, a figure of £16 per appointment was used.26  On average women 
 
29 attended for 4.2 sessions out of the possible 5 therefore we applied an 84% uptake.rate. 
14  
3 
 
4 Based on the questionnaire responses regarding further treatment received, and published cost estimates of 
 
5 the various treatment courses (surgery £1,044;26  pessary £229.45;27,28  referral for physiotherapy £170.24, 
 
6 oestrogen/HRT £195.5127), the difference between the groups in mean cost of subsequent treatment was 
 
7 £38.63 (95% CI [-£41.95, £126.41], p=0.34). The mean cost per woman in the control group was £306.86 
 
8 (95% CI [£250.74, £368.29]), and intervention group £268.23 (95% CI [£210.35, £333.59]). Overall the 
 
9 net cost of the intervention per woman was £170.24 - £38.63 = £131.61. 
 
10 
 
11 This cost is set against a significant difference between groups in the primary clinical outcome measure. The 
 
12 net cost per one-point improvement in POP-SS was £131.61/1.52, or £86.59. When we consider the 95% 
 
13 confidence interval around the difference in change in POP-SS from baseline (0.46 to 2.59), the cost per 
 
14 point improvement on POP-SS ranges from £51.81 to £286.11. When we consider the 95% confidence interval 
 
15 around the net costs (£170.24-£126.41 to £170.24+£41.95) the cost per point improvement on POP-SS 
 
16 ranges from £28.84 to £139.60. 
 
17 Discussion 
 
18 We found a greater reduction in prolapse symptoms in the PFMT group at 12 months when compared to the 
 
19 control group. The difference was both statistically significant, and of a magnitude that would be important to 
 
20 women, as it exceeded the minimally important change for the POP-SS.29  This finding was supported by a 
 
21 higher uptake of supplementary treatments (principally PFMT) in the control group after 6 months indicating 
 
22 residual need; a lower prevalence of each individual prolapse symptom, as well as in bladder, bowel and 
 
23 sexual symptoms, and better quality of life in the intervention group after 6 months of PFMT. Women in the 
 
24 intervention group were also more likely to say their prolapse was “better” at both 6 and 12 months. While 
 
25 more women in the intervention group demonstrated improvement in prolapse stage, this was not significantly 
 
26 different between the groups. Subgroup analyses indicated that these findings of effectiveness held regardless 
 
27 of the woman’s prolapse stage or type, her age or her attitude towards having surgery. 
 
28 
15  
3 Since there was a high degree of uptake of some form of PFMT in the control group before the primary 
 
4 outcome assessment at 12 months, and no evidence of differential use of other non-PFMT interventions, it 
 
5 seems plausible that the intention-to-treat treatment effect estimate is an underestimate of the benefit 
 
6 associated with PFMT at 12 months. We are confident therefore that the significant treatment effects reported 
 
7 represent real effects that are of importance to women and clinicians. 
 
8 
 
9 By 12 months a greater proportion of control women than intervention women had received further prolapse 
 
10 treatment (49% versus 23%), predominantly PFMT between 6 and 12 months: a quarter of the control group 
 
11 women sought a referral to physiotherapy, giving them access to PFMT, indicating residual need for treatment. 
 
12 However, similar proportions of women in both groups had undergone prolapse repair surgery by 12 months 
 
13 (11% intervention and 10% control), or received a pessary. 
 
14 
 
15 The observation that at 12 months the control group were as likely to be exercising as the intervention group 
 
16 may be explained partly by the uptake of physiotherapy in the control group. It is encouraging that almost 80% 
 
17 of intervention women were still exercising at 12 months, as long-term adherence is an important consideration 
 
18 for the effectiveness of this intervention. 
 
19 
 
20 The net cost of the intervention was £131.61 per woman. The main determinant of the cost is of providing the 
 
21 intervention. The main area of uncertainty is the longer-term impact of PFMT on the need for subsequent 
 
22 treatments such as pessaries, physiotherapy and surgery: our results are based on the trial follow-up period 
 
23 and we cannot exclude the possibility that treatments have been delayed rather than avoided. The sensitivity 
 
24 analyses show the plausible ranges around our results, however there are reasons for believing that the higher 
 
25 costs are unlikely, notably that the expenditure on the intervention is a one-off so all the costs have been 
 
26 incurred and it is plausible that the benefits in terms of reduced symptoms and treatments avoided will 
 
27 continue to accrue over time. 
 
28 
16  
3 Assuming that intervention women gained 10% on their quality of life for a year as a result of the intervention, 
 
4 the cost per quality adjusted life year (QALY) gained is around £16,000. This level of cost per QALY is 
 
5 commonly accepted as worthwhile by organisations such as the National Institute for Health and Clinical 
 
6 Excellence in the UK. 
 
7 
 
8 The main strengths of the trial were its size, rigour and pragmatic design, with the intervention being relevant 
 
9 to UK NHS practice, and potentially to other similar health systems worldwide, and the outcomes being 
 
10 woman-centred. Participants’ compliance with trial processes and the intervention were generally high. Unlike 
 
11 other trials in this area, our main focus was the prolapse symptoms which led the women to seek treatment, 
 
12 and which we used to measure treatment success. 
 
13 
 
14 In terms of limitations, we achieved 88% of our target sample size of 506, and experienced a lower 
 
15 questionnaire response rate at 12 months (66%) than expected, despite postal and telephone reminders. 
 
16 However, as the observed SD of the POP-SS was smaller than originally assumed, we nevertheless had 
 
17 sufficient power to identify important differences. There was no evidence of differential dropout as the response 
 
18 rate was similar in both trial groups, and results were also found to be robust to missing data. Not all women 
 
19 had a prolapse assessment at 6 months; therefore there was also attrition in the POP-Q responses (75% 
 
20 intervention, 77% control). This may have contributed to the non-significant POP-Q finding. There was 
 
21 significant crossover of control women to the intervention due to their uptake of PFMT after 6 months, and this 
 
22 makes interpretation of the findings more challenging. A further limitation is the short follow-up period of 12 
 
23 months: due to natural fluctuation in prolapse symptoms and the effect of different treatment modalities, clinical 
 
24 and cost differences between the groups might be expected to change with time. Women included in this trial 
 
25 were treatment-naïve, presenting for treatment for the first time. However, PFMT may also be effective in 
 
26 enhancing surgical or pessary treatment, or for use after surgical failure, or shortly after childbirth and these 
 
27 situations need further research. In the economic analysis we did not estimate QALYs gained since we found 
 
28 in our pilot work that the SF-12 was insensitive to meaningful changes in prolapse symptoms in this 
 
29 population. Decision-makers therefore must interpret the results based on a careful reading of the symptoms 
17  
3 women suffered and the extent to which these were relieved. The lack of other economic studies in this field 
 
4 makes it difficult to compare results, and we look forward to future studies that provide comparisons for these 
 
5 results. 
 
6 
 
7 There are six other randomised studies published to date comparing PFMT with a control.12,30–34 Three of these 
 
8 are pilot trials making it problematic to draw conclusions from their findings due to their developmental nature 
 
9 and small sample sizes.12,30,31 Three other full-sized trials have been published.32–34 The Piya-Anant trial32 had 
 
10 methodological limitations and high risk of bias and cannot reliably contribute to the evidence-base. No 
 
11 information was provided on the processes of random sequence generation or allocation concealment; there 
 
12 was no reporting of attrition, selective reporting of only a subgroup of the women randomised, and uncertainty 
 
13 as to whether the analysis was an intention to treat analysis. 
 
14 
 
15 Of the remaining two trials, the Brækken single-centre trial33 of PFMT versus control randomised 109 women 
 
16 with stage I to III prolapse, of which a subgroup of only 69 women were symptomatic and hence comparable 
 
17 to our population. The very intensive PFMT regimen consisted of weekly appointments for 3 months, followed 
 
18 by bi-weekly appointments for 3 months: a model of treatment that it would not be possible to deliver in the 
 
19 UK and many other countries. Kashyap34 recently reported on a single-centre trial in women with stage I to III 
 
20 prolapse which compared taught PFMT plus a self instruction manual (n=70) with the self instruction manual 
 
21 alone as control (n=70). A single person delivered the PFMT intervention to all women. The content of the 
 
22 manual was not described and therefore it is unclear what written instruction the control group received. More 
 
23 importantly, four women transferred from the control group to the PFMT plus manual group and it is not clear 
 
24 in which group these women were analysed: until this is clarified the results have limited utility. 
 
25 
 
26 Symptom benefit from PFMT was reported by both Braekken33 and Kashyap34. Braekken analysed women with 
 
27 symptoms at baseline, and found that those who had received PFMT compared to controls were more likely to 
 
28 have reduced frequency of symptoms (74% versus 31%) and reduced bother (67% versus 42%). Kashyap 
 
29 reported a significantly greater mean reduction in POP-SS score post-intervention for the PFMT plus manual 
18  
3 group compared to the control group (2.99 versus 1.25). Neither trial sought evidence about longer term 
 
4 outcomes or effect on the uptake of other treatments. 
 
5 
 
6 Braekken33 also reported that PFMT improved POP-Q stage: 19% had an improved stage in the intervention 
 
7 group versus 8% in the control group (11% risk difference). Our finding for POP-Q was marginally non- 
 
8 significant but of a similar size (risk difference 7.5%, 95% CI [-1.4%, 16.4%]). The most likely reason for the 
 
9 non-significant finding in our trial is that the study was not powered to show a difference for this outcome. 
 
10 Data on change in the POP-Q or prolapse stage in the Kashyap trial were not adequately reported to allow 
 
11 comparison.34 
 
12 
 
13 We chose our primary outcome measure to be symptom change: this is usually the driver for seeking 
 
14 treatment for prolapse, and hence the most important outcome for women. It is increasingly recognised that 
 
15 there is little correlation between ‘stage’ of prolapse and the prolapse symptoms ascribed to it.35,36 Therefore it 
 
16 is not surprising that, as we found, an improvement in symptoms does not necessarily correspond to an 
 
17 improvement in stage. 
 
18 
 
19 We found that 45% of women in the control group reported that their prolapse was better at 12 months. This 
 
20 is in part due to the fact that around half (49%) of these women had received further treatment for prolapse 
 
21 by this time-point. Although significantly more women in the intervention group compared to the control group 
 
22 reported their prolapse was better (57% versus 45%), the remaining 43% reported no change or worse 
 
23 prolapse. Thus we conclude that a substantial group of women did not benefit. One potential reason is that a 
 
24 more intensive intervention might be required for some women. Another is that some types or stages of 
 
25 prolapse do not respond to PFMT as well as others and hence better selection of women for PFMT might be 
 
26 required. Although our subgroup analyses (for prolapse stage and type, age and motivation for surgery) did 
 
27 not support these hypotheses, the analyses were exploratory and under-powered to draw firm conclusions. 
 
28 
19  
3 It is recognised that prolapse can regress with time, and this could partially explain the improvement we 
 
4 observed. Three studies of the epidemiology of prolapse have concluded that prolapse can both progress and 
 
5 regress.37–39 The studies by Handa37 and Bradley38 looked at change in severity of prolapse, but in populations 
 
6 older than our own. The study by Miedel39 is most relevant for comparison as it examined both symptoms and 
 
7 stage of prolapse over time in women with a mean age of 56. They found that 44% of stage I prolapses had 
 
8 regressed (improved) to stage 0, 24% of stage II showed regression, and 64% (95% CI [56%, 72%]) of 
 
9 women had a reduction in symptoms by 5 years. However the study population was mainly non-consulting 
 
10 women identified by a positive questionnaire response to “a feeling of a vaginal bulge”, rather than women 
 
11 who were actively seeking treatment for prolapse. As the authors pointed out, results cannot automatically be 
 
12 generalised to patients who present to health care. Thus we do not know to what extent women in our trial 
 
13 naturally improved. However, we would expect that any natural regression or progression would occur equally 
 
14 in both groups by virtue of the group allocation, and hence the observed significant differences between the 
 
15 groups must be due to the intervention. 
 
16 
 
17 Our trial constitutes the largest, rigorous, pragmatic multicentre trial of PFMT for prolapse, with the longest 
 
18 follow-up, and as such provides the necessary evidence to support changes in clinical practice. However the 
 
19 resource implications of implementing these findings need to be considered. The physiotherapists delivering the 
 
20 trial intervention were specialists in women’s health; their numbers are limited and workload is large, currently 
 
21 consisting mainly of the management of urinary incontinence. With the establishment of an evidence-base for 
 
22 PFMT in the management of prolapse, healthcare providers will need to invest in extra resources to ensure 
 
23 that a similar service can be provided for women with prolapse. In addition, outwith the clinical arena, the role 
 
24 of pelvic floor muscle exercises in alleviating prolapse symptoms is an important public health message, which 
 
25 needs to be shared widely with females of all ages. 
 
26 
 
27 In summary, we found individualised PFMT was effective, leading to greater reduction in prolapse symptoms in 
 
28 the PFMT group. The net cost of the intervention was £131.61 per woman, and under plausible conditions this 
 
29 would prove cost-effective. 
20  
3 
 
4 We conclude that PFMT should be recommended for the conservative management of prolapse. Effectiveness 
 
5 of PFMT in the long-term, in women who have had previous prolapse surgery, in conjunction with pessary use 
 
6 and within populations of women with different types or combinations of prolapse should be investigated 
 
7 further. 
 
8 Word count 5624 
 
9 
 
10 Research in context (box) 
 
11 Systematic review 
 
12 The Cochrane review on the topic of conservative management of prolapse was updated in 2011 by two of the 
 
13 authors, prior to the completion of the analysis of the current trial. Four trials compared PFMT with a 
 
14 control,12,30,32,33  but two were at significant risk of bias;30,32  of the remaining two, one was the pilot study 
 
15 preceding the current trial.12 Prolapse symptoms were measured differently in the three trials where this was 
 
16 reported,12,30,33  however all three found greater improvement in symptoms in the PFMT group. Limited data 
 
17 from the two trials with low risk of bias12,33 suggested that PFMT increases the chance of an improvement in 
 
18 prolapse stage compared to no PFMT. 
 
19 Interpretation 
 
20 Our trial represents the largest, rigorous, pragmatic trial of PFMT versus control for prolapse, and as such 
 
21 provides important robust evidence to inform clinical practice. Its findings confirm the findings of other smaller 
 
22 or less rigorous studies that PFMT is beneficial in terms of reducing women’s prolapse symptoms. The findings 
 
23 have implications for a range of healthcare professionals who care for women with prolapse (general 
 
24 practitioners, gynaecologists, physiotherapists, nurses, healthcare managers) and for women themselves. 
25 
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3 Table 1. Baseline characteristics 
 
 Intervention (N=225) Control (N=222) 
Age (mean [SD]), n 56.20 [11.60], 225 57.50 [11.39], 222 
BMI (mean [SD]), n 27.15 [4.99], 214 27.42 [4.57], 210 
Parity (median [IQR]), n 2 [2-3], 223 2 [2-3], 217 
   
Stage of prolapse# (freq [%]):   
Stage I 23/225 (10.2) 18/222 (8.1) 
Stage II (above the hymen) 48/225 (21.3) 47/222 (21.2) 
Stage II (at or below the hymen) 116/225 (51.6) 127/222 (57.2) 
Stage III 38/225 (16.9) 29/222 (13.1) 
Stage IV 0/225 (0.0) 1/222 (0.4) 
   
Type of prolapse (freq [%]):   
Anterior 23/225 (10.2) 25/220 (11.4) 
Posterior 13/225 (5.8) 11/220 (5.0) 
Anterior + posterior 54/225 (24.0) 54/220 (24.5) 
Anterior + upper 27/225 (12.0) 22/220 (10.0) 
Posterior + upper 6/225 (2.7) 8/220 (3.6) 
Anterior + posterior + upper 102/225 (45.3) 100/220 (45.5) 
   
Duration of prolapse symptoms in months (median [IQR], n) 12 [6-24], 196 12 [6-24], 201 
Baseline POP-SS score (mean [SD]), n 10.04 [6.0], 224 9.51 [5.64], 222 
   
Symptom reported in last 4 weeks (n/N [%]):   
Something coming down 193/219 (88.1) 195/219 (89.0) 
Discomfort worse when standing 140/221 (63.3) 147/220 (66.8) 
Abdominal pain when standing 153/222 (68.9) 145/217 (66.8) 
Lower back heaviness 131/222 (59.0) 125/216 (57.9) 
27  
 
Strain to empty bladder 138/221 (62.4) 109/218 (50.0) 
Feel bladder not empty 159/221 (71.9) 152/218 (69.7) 
Feel bowel not empty 154/221 (69.7) 140/222 (63.1) 
   
Faecal urgency* 138/223 (61.9) 135/221 (61.1) 
Faecal incontinence* 60/223 (26.9) 55/222 (24.8) 
   
Urinary incontinence 145/225 (64.4) 156/221 (70.6) 
Urinary incontinence score (ICIQ UI SF+) (median [IQR]), n 4 [0-7], 218 4 [0-7], 216 
3 #  POP-Q stage reported here was calculated at the analysis stage using a specially developed programme using the 9 
 
4 individual POP-Q measurements recorded by the gynaecologist. On occasion this differed from the stage assigned by the 
 
5 gynaecologist which determined women’s trial eligibility. 
 
6 + ICIQ UI SF score: 0=no incontinence, no interference with everyday life; 21=maximum leakage and interference 
 
7 * faecal urgency = sudden, irresistible need to have a bowel movement; faecal incontinence = any involuntary loss of faecal 
 
8 material 
 
9 
 
10 
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3 Table 2. Intervention group women’s attendance at physiotherapy appointments 
 
No. of appointments attended (%) Frequency (%) 
 
N=222* 
0 10/222 (4.5%) 
1 9/222 (4%) 
2 10/222 (4.5%) 
3 15/222 (7%) 
4 22/222 (10%) 
5 156/222 (70%) 
4 * missing data for 3 women from the intervention group 
 
5 
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Table 3. Self-reported prolapse symptoms at 6 and 12 months 
 
 
 
 6 months   12 months   
 Intervention Control Adjusted** difference 
in mean change from 
baseline, 
(95% CI) p-value 
Intervention Control Adjusted** difference in 
mean change from 
baseline, 
95% CI, p-value 
POP-SS (mean (SD), n)* 6.56 (5.09), 188 9.17 (5.81), 189  5.74 (4.89) 145 7.04 (5.43), 139  
Reduction in POP-SS from baseline 
 
(mean (SD)) 
3.16 (4.78) 0.12 (3.86) 2.84 
 
(2.05, 3.63) 
 
<0.0001 
3.77 (5.62) 2.09 (5.39) 1.52 
 
(0.46, 2.59), 0.0053 
       
Prolapse symptoms reported in last 4 weeks p-value   p-value 
Feeling of something coming down 136/185 (73.5%) 162/187 (86.6%) 0.0001 98/139 (70.5%) 102/138 (73.9%) 0.09 
Discomfort worse when standing 81/184 (44.0%) 122/185 (65.9%) <0.0001 54/141 (38.3%) 78/137 (56.9%) 0.0016 
Abdominal pain when standing 89/187 (47.6%) 114/184 (62.0%) 0.0001 56/143 (39.2%) 69/135 (51.1%) 0.0077 
Lower back heaviness 88/187 (47.1%) 108/182 (59.3%) 0.0036 63/143 (44.1%) 68/137 (49.6%) 0.10 
Strain to empty bladder 87/185 (47.0%) 106/185 (57.3%) 0.0325 67/143 (46.9%) 64/136 (47.1%) 0.95 
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Feel bladder not empty 109/187 (58.3%) 129/184 (70.1%) 0.0009 80/144 (55.6%) 85/137 (62.0%) 0.56 
Feel bowel not empty 111/187 (59.4%) 134/184 (72.8%) 0.0014 85/140 (60.7%) 91/137 (66.4%) 0.41 
       
Days with prolapse symptoms in the 
last 4 weeks† 
137/185 (74.1%) 162/186 (87.1%) 0.0001 95/143 (66.4%) 104/139 (74.8%) 0.0233 
       
How prolapse is now compared to start of study start p-value   p-value 
Better 98/187 (52%) 32/189 (17%) <0.0001 83/145 (57.2%) 63/141 (44.7%) 0.0125 
The same 77/187 (41%) 114/189 (60%)  49/145 (33.8%) 52/141 (36.9%)  
Worse 12/187 (6%) 43/189 (23%)  13/145 (9.0%) 26/141 (18.4%)  
 
* POP-SS score, 0=no symptoms, 28 = all 7 symptoms all the time 
 
** Adjusted for baseline POP-SS, POP-Q stage, centre and whether the woman was motivated to have surgery 
 
†  ‘number of days with symptoms’ question had a 7 category response (0 “none of the time” to 6 “every day”). Mann-Whitney test used on the number of categories changed since baseline 
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Table 4. Self-reported impact of prolapse symptoms, and prevalence of urinary and bowel symptoms at 6 and 12 months$ 
 
 6 months   12 months   
 Intervention Control p-value Intervention Control p-value 
Prolapse symptoms: 
 
interference^ with: median (IQR#), n 
      
Everyday life 1 (0-3), 188 3 (1-6), 189 0.001 1 (0-3), 145 1 (0-4), 138 0.095 
Physical activity 2 (0-5), 187 3 (0-6), 189 0.010 1 (0-3), 128 1 (0-4), 124 0.251 
Social activity 0 (0-3), 187 1 (0-4), 189 0.012 0 (0-1), 128 0 (0-2), 123 0.173 
Personal hygiene 0 (0-2), 188 1 (0-5), 189 0.003 0 (0-2), 128 1 (0-3), 124 0.079 
Prolapse symptoms: 
 
interference with sex life: n/N (%) 
      
Not at all 75/146 (51.4%) 53/145 (36.6%)   
 
 
0.033 
52/95 (54.7%) 47/95 (49.5%)   
 
 
0.510 
A little 35/146 (24.0%) 46/145 (31.7%) 25/95 (26.3%) 29/95 (30.5%) 
     
Somewhat 19/146 (13.0%) 30/145 (20.7%) 11/95 (11.6%) 10/95 (10.5%) 
A lot 17/146 (11.6%) 16/145 (11.0%) 7/95 (7.4%) 9/95 (9.5%) 
Bladder symptoms:       
Urine leakage n/N (%) 103/188 (54.8%) 129/189 (68.3%) 0.01 72/132 (54.5%) 77/128 (60.2%) 0.430 
ICIQ SF UI score+ 
median (IQR), n 
3 (0-5), 183 4 (0-7), 181 <0.001 3 (0-5), 126 3 (0-6), 126 0.118 
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Bowel symptoms:* n/N (%)       
Faecal urgency 96/188 (51.1%) 114/189 (60.3%) 0.041 63/130 (48.5%) 71/126 (56.3%) 0.120 
Faecal incontinence 42/188 (22.3%) 47/189 (39.7%) 0.479 23/130 (17.7%) 34/127 (26.8%) 0.072 
$ women were asked to answer questions in relation to the last four weeks 
 
^ Prolapse-related interference scores range from 0=not at all to 10=a great deal 
 
+ ICIQ UI SF score: 0=no incontinence, no interference with everyday life; 21=maximum leakage and interference 
 
* faecal urgency = sudden, irresistible need to have a bowel movement; faecal incontinence = any involuntary loss of faecal material 
 
# IQR = interquartile range 
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Table 5. Change in prolapse stage (using POP-Q system) at 6 months, and uptake of further prolapse treatment by 12 months 
 
 Intervention Control p-value 
Change in POP-Q stage from baseline to 6 months N=1 68 N=1 71  
+2 stages 4/168 (2.4%) 9/171 (5.3%)  
+1 stages 26/168 (15.5%) 29/171 (17.0%)  
no change 93/168 (55.4%) 100/171 (58.5%)  
-1 stage 34/168 (20.2%) 25/171 (14.6%)  
-2 stages 11/168 (6.5%) 8/171 (4.7%)  
    
    
    
    
    
Further treatment received by 12 months* N=145 N=143  
Any further treatment received 35/145 (24.1%) 71/143 (49.6%) <0.0001 
Surgery 16/145 (11.0%) 14/143 (9.8%) 0.84 
Pessary 8/145 (5.5%) 16/143 (11.2%) 0.13 
Physiotherapy referral 2/145 (1.4%) 38/143 (26.6%) <0.0001 
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Oestrogen, drugs, other 14/145 (9.7%) 15/143 (10.5%) 0.85 
* The values of N represent the number of women who reported whether or not they received any further treatment at 12 months and are the denominators for the percentages. 
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Figure 1. CONSORT flow diagram 
 
 
 
 
 
Enrollment  
Assessed for eligibility (n=2093) 
 
 
 
Excluded (n=1646) 
◆ Not meeting inclusion criteria (n=1490) 
◆ Declined to participate (n=156) 
 
 
 
 
Randomised (n=447) 
 
 
 
 
 
 
 
Allocated to intervention (n=225) 
◆ Received allocated intervention (n=212) 
◆ Did not receive allocated intervention (did not 
attend any appointments) (n=10) 
◆ Missing (n=3) 
Allocation   
Allocated to control (lifestyle advice leaflet) 
(n=222) 
 
 
 
 
 
 
Lost to follow-up (withdrew from questionnaire 
follow-up) (n=14) 
Discontinued intervention (n=30): 
• Did not have time to participate: 7 
• DNAd appointments/unable to contact to 
rearrange: 7 
• Became ineligible post-randomisation: 5 
• Referred to gynaecology/for surgery: 5 
• Difficulties with travel to appointments: 3 
• PFMT thought making symptoms worse: 2 
• Declined to complete 12 month 
questionnaire: 1 
Follow-Up  
 
Lost to follow-up (withdrew from questionnaire 
follow-up) (n=12) 
 
 
 
 
 
 
Analysed 
• baseline (n=225) 
• 6 month questionnaire (n=189) 
• 6 month POP-Q (n=168) 
• 12 month questionnaire (n=150) 
Excluded from analysis (n=0) 
Analysis   
Analysed 
• baseline (n=222) 
• 6 month questionnaire (n=199) 
• 6 month POP-Q (n=171) 
• 12 month questionnaire (n=145) 
Excluded from analysis (n=0) 
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